Novartis is moving its UK headquarters to London, in a multi-million pound investment in UK life sciences, which will be complete by January 2020.
The Swiss drugs giant said it is relocating its UK headquarters to The WestWorks building on the White City Place campus, in a bold move to join London’s latest emerging life sciences cluster.
The WestWorks is home to a number of technology and innovation companies.
The area is emerging to be London’s latest life sciences cluster and is quickly becoming home to a number of pioneering life sciences companies, as well as Imperial College London’s major new research and innovation campus.
“The nature of healthcare and medicine is changing and as we pivot towards becoming a focused medicines company, powered by digital and data, we want to be closer to our customers and partners, and become better networked in the healthcare and life science ecosystem,” said Haseeb Ahmad, Novartis UK country president.
He continued, “White City is quickly becoming one of the UK’s life sciences and technology districts, and the ethos of The WestWorks campus complements how we work to deliver on our strategy to reimagine medicine.”
Professor David Gann, VP of innovation at Imperial College also commented on the move, stating: “Novartis is a natural fit for White City’s booming life sciences ecosystem, and we hope that this move will pave the way to new collaborations and partnerships to enhance our work in this area.”
By Anna Smith
Source: Pharma Times
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.
